跳至主要内容
临床试验/ACTRN12607000249459
ACTRN12607000249459已完成4 期

Inhaled corticosteroids (ICS) in subjects with mild to moderate Chronic Obstructive Pulmonary Disease (COPD). Does Bronchodilator reversibility and an asthmatic airway phenotype predict for ICS response?

GlaxoSmithKline0 个研究点目标入组 35 人开始时间: 2007年5月8日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 75 Years(—)
性别
All

入选标准

  • A physician diagnosis of COPD and evidence of airflow limitation on spirometry.

排除标准

  • Potential participants were interviewed and examined by a respiratory physician and any history suggestive of asthma, i.e. symptoms present in childhood, related atopic disorders, eczema or hay fever, significant day-to-day variability or prominent nocturnal symptoms, or a history of wheeze rather than progressive breathlessness and any previous use of ICS excluded that subject from further participation. Other exclusion criteria included significant uncontrolled co-morbidities such as diabetes, angina or cardiac failure, and other co-existing respiratory disorders, i.e. pulmonary fibrosis, lung cancer and bronchiectasis.

研究者

相似试验